Hikma Pharmaceuticals (HIK) News Today → Urgent Nvidia Warning (From Altimetry) (Ad) Free HIK Stock Alerts GBX 1,978 -5.00 (-0.25%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 1:33 PM | finanznachrichten.deActive Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarketsMay 12, 2024 | americanbankingnews.comHikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 10, 2024 | insidertrades.comHikma Pharmaceuticals PLC (LON:HIK) Insider Buys £14,565.44 in StockMay 9, 2024 | americanbankingnews.comRiad Mishlawi Acquires 736 Shares of Hikma Pharmaceuticals PLC (LON:HIK) StockMay 7, 2024 | marketbeat.comHikma Pharmaceuticals' (HIK) Equal Weight Rating Reaffirmed at BarclaysBarclays reiterated an "equal weight" rating and issued a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday.April 26, 2024 | markets.businessinsider.comEuropean Stocks Close On Strong Note As Investors Cheer Earnings UpdatesApril 26, 2024 | marketbeat.comHikma Pharmaceuticals' (HIK) Hold Rating Reiterated at Berenberg BankBerenberg Bank reissued a "hold" rating and issued a GBX 2,000 ($24.70) price objective on shares of Hikma Pharmaceuticals in a research report on Thursday.April 25, 2024 | thetimes.co.ukThe drugs do work as AstraZeneca leads the packApril 25, 2024 | msn.comHikma: Pharma giant starts year strong as new product sales surge in key marketsApril 25, 2024 | lse.co.ukHikma Pharmaceuticals backs outlook after making strong start to 2024April 24, 2024 | msn.comIs this FTSE growth superstar set to soar even higher on new drug results?April 17, 2024 | msn.comCarisma Therapeutics (CARM) Price Target Decreased by 10.00% to 9.18April 14, 2024 | seekingalpha.comHKMPY Hikma Pharmaceuticals PLCApril 11, 2024 | markets.businessinsider.comEuropean Stocks Close Lower Amid Uncertainty About Interest RatesApril 11, 2024 | uk.finance.yahoo.comI’m considering these 3 undervalued pharma stocks to buy for my portfolio in AprilApril 8, 2024 | marketbeat.comBarclays Reiterates "Equal Weight" Rating for Hikma Pharmaceuticals (LON:HIK)Barclays restated an "equal weight" rating and set a GBX 2,000 ($25.11) price objective on shares of Hikma Pharmaceuticals in a research report on Monday.April 7, 2024 | finance.yahoo.comGeneric Medicine Market To Reach USD 818.3 Billion By 2032, Says DataHorizzon ResearchApril 3, 2024 | msn.comFTSE 100 Live: Index slips after topping 8000 and nearing record high, Superdry plungesMarch 22, 2024 | finance.yahoo.comGlobal Lidocaine Hydrochloride Market Report 2024, by Dosage Form, Application, Distribution Channel and RegionMarch 21, 2024 | finance.yahoo.comLidocaine Hydrochloride Market Forecasted to Reach USD 1.56 Billion by 2034 with Robust Growth in Asia Pacific RegionMarch 17, 2024 | msn.comBig pharma shakeup in Morocco as Sanofi sells business to HikmaMarch 15, 2024 | finanznachrichten.deHyloris Pharmaceuticals SA: Hyloris Reports Full Year Results for 2023 & Provides Business OutlookMarch 14, 2024 | uk.finance.yahoo.comHyloris Reports Full Year Results for 2023 & Provides Business OutlookMarch 13, 2024 | morningstar.comFTSE 100 Closes Up 0.12% Ahead of U.K. Jobs DataMarch 13, 2024 | markets.businessinsider.comBioHarvest Sciences Announces New Strategic Hires for CDMO Services Business UnitMarch 4, 2024 | msn.comThe 9th edition of the GCC Regulatory Affairs Pharma Summit is set to convene in Dubai in 2024, marking a significant gathering of over 400 professionals, including regional ...February 27, 2024 | finanznachrichten.deHyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In CanadaFebruary 27, 2024 | finance.yahoo.comHyloris Announces Launch of Maxigesic® IV in the U.S. and approval In CanadaFebruary 27, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) PT Raised to GBX 2,000 at Berenberg BankBerenberg Bank boosted their target price on Hikma Pharmaceuticals from GBX 1,960 ($24.86) to GBX 2,000 ($25.37) and gave the stock a "hold" rating in a research report on Monday.February 27, 2024 | marketbeat.comHikma Pharmaceuticals PLC (LON:HIK) Given Average Rating of "Moderate Buy" by AnalystsShares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have assigned aFebruary 22, 2024 | thetimes.co.ukHikma beats profit estimates thanks to narcolepsy drugFebruary 22, 2024 | msn.comFTSE 100 Live 22 February: Lloyds results, shares start higher after Nvidia beats expectationsFebruary 22, 2024 | lse.co.ukTOP NEWS: Hikma boosts dividend after year of "significant progress"February 22, 2024 | marketwatch.comHikma Pharmaceutical FY EPS 85cFebruary 22, 2024 | marketbeat.comHikma Pharmaceuticals PLC (LON:HIK) Announces Dividend of $0.47Hikma Pharmaceuticals PLC (LON:HIK) announced a dividend on Thursday, February 22nd. Investors of record on Thursday, March 21st will be paid a dividend of $0.47 per share on Friday, May 3rd. This represents a yield of 1.86%. The ex-dividend date is Thursday, March 21st. This is a positive change from Hikma Pharmaceuticals's previous dividend of $0.25. The official announcement can be accessed at this link.February 21, 2024 | finance.yahoo.comHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityFebruary 15, 2024 | marketbeat.comHikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200 Day Moving Average of $1,946.54Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above Two Hundred Day Moving Average of $1,946.54February 8, 2024 | msn.comHigher-dose naloxone spray didn't save more lives, researchers findFebruary 8, 2024 | finance.yahoo.comHigh-dose opioid reversal spray no better than lower dose in field, US study findsFebruary 7, 2024 | msn.comNZ-developed intravenous product launches in United StatesFebruary 5, 2024 | news.yahoo.comMass. AG announces opioid settlements with two companies. State to get $8 million.February 5, 2024 | msn.comVirginia expected to receive $2M+ from opioid manufacturer lawsuitFebruary 2, 2024 | msn.comAd agency tied to Purdue Pharma settles opioid claims for $350 millionFebruary 1, 2024 | msn.comOregon Supreme Court rules lawmakers cannot seek reelection after Senate boycottFebruary 1, 2024 | msn.comOpioid settlements announced with two companiesFebruary 1, 2024 | msn.comOxyContin marketer, opioid maker announce settlements totaling $500 millionFebruary 1, 2024 | thetimes.co.ukHikma reaches US settlement over opioid epidemicFebruary 1, 2024 | msn.comMassachusetts receives $8 million in opioid settlement, marketing firm ‘helped fuel the nationwide opioid crisis’February 1, 2024 | msn.comMassachusetts will receive $8 million from marketing company as part of opioid settlementJanuary 20, 2024 | marketbeat.comHikma Pharmaceuticals PLC (LON:HIK) Receives Consensus Rating of "Moderate Buy" from AnalystsHikma Pharmaceuticals PLC (LON:HIK - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendati Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. HIK Media Mentions By Week HIK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HIK News Sentiment▼0.900.42▲Average Medical News Sentiment HIK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HIK Articles This Week▼12▲HIK Articles Average Week Get Hikma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HUTCHMED News Indivior News Dechra Pharmaceuticals News ConvaTec Group News EMIS Group News Genus News Smith & Nephew News Alliance Pharma News Allergy Therapeutics News Animalcare Group News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:HIK) was last updated on 5/19/2024 by MarketBeat.com Staff From Our Partners[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
